Phase 3 findings show infigratinib significantly improved annualized height velocity vs placebo in children living with achondroplasia. Topline data were announced from a phase 3 trial evaluating ...

Please provide your email address to receive an email when new articles are posted on . Children receiving infigratinib in a phase 3 trial had a 1.74 cm per year greater increase in annualized height ...

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, the most common form of dwarfism, that could form the basis of regulatory ...

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events. BridgeBio Pharma’s experimental drug for the ...

The meteoric rise of GLP-1 drugs for weight loss has raised concerns about potential malnutrition and even the comeback of scurvy. (The Hill) An $80-per-month produce prescription subsidy failed to ...

Achondroplasia is the most common form of dwarfism, affecting about 1 in 25,000 live births. The condition is caused by a gain-of-function pathogenic variant in the gene that encodes fibroblast growth ...

Achondroplasia, a genetic condition affecting bone growth, occurs in approximately one in every 15,000 to 40,000 newborns and impacts an estimated 55,000 people in the U.S. and European Union. This ...

On 12 February 2026, BridgeBio Pharma reported positive topline Phase 3 PROPEL 3 results for oral infigratinib in children with achondroplasia, showing statistically significant gains in annualized ...

Bridgebio Pharma Inc. disclosed positive top-line results from Propel 3, the global phase III pivotal study of oral infigratinib in children with achondroplasia. Change from baseline in annualized ...

Feb 12 (Reuters) - BridgeBio Pharma (BBIO.O), opens new tab said its experimental therapy boosted growth rates in children with a rare genetic disorder that causes dwarfism, sending the company's ...

- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p<0.0001) - Change from baseline in AHV was superior to placebo at Week 52 with a mean treatment difference ...